Portfolio manager comments — Q3 2025
The fund's positive relative performance during the year came to an abrupt end in July. The fund rose approximately 0.2% during the quarter, while its benchmark, the SIX Sweden SRI Gross Index, increased by about 3.40%.
One explanation for the weak performance is the share price decline in the animal health company Vimian, where an unexpected CEO change caused the stock to lose around one-third of its market capitalization. Despite the surprising announcement, we consider the market reaction exaggerated, especially considering that the company’s earnings forecasts have actually been revised upwards since the reporting date.
The fund’s performance has also been weighed down by the approximately 40% decline in software company Truecaller since summer. The company derives a significant portion of its revenues from India, making the recent strengthening of the Swedish krona negatively impact profits when reported in SEK. However, the underlying business continues to perform strongly. Other key negative contributors to relative performance largely consist of mid-sized growth companies, and we note with some surprise the rapid rise in the risk premium for this segment.
The largest positive contributor to the fund’s return during the quarter was clothing company H&M, which reported quarterly figures in September with operating profits exceeding market expectations by 34%. This reinforced the price appreciation that had begun over the summer.
During the quarter, the fund sold its entire holdings in healthcare companies Ambea and Attendo and significantly reduced exposure to more short-cyclical companies such as Sandvik, Trelleborg, and SKF. In return, the fund invested in Dometic and increased existing holdings in Alfa Laval, Atlas Copco, Epiroc, and Boliden. Overall, the portfolio composition has not changed significantly. The fund remains positioned for an economic recovery and a lower risk premium on mid-sized companies.